New Mountain acquires Mallinckrodt Baker
An affiliate of New Mountain Capital announced the completion of its acquisition of Mallinckrodt Baker from Covidien for approximately $280 million.
An affiliate of New Mountain Capital announced the completion of its acquisition of Mallinckrodt Baker from Covidien for approximately $280 million.
Headquartered in New Jersey, Mallinckrodt Baker manufactures and markets high-purity chemicals and related services and products under brand names, J.T.Baker and Mallinckrodt Laboratory Chemicals. According to the company these products are widely used in research and quality control laboratories, microelectronics, environmental testing laboratories and universities, and for manufacturing in the pharmaceutical, biotechnology and other industrial markets. The company’s operations will continue as usual, with no supply interruptions or process changes anticipated as a result of the sale.
“We look forward to working with the Mallinckrodt Baker leadership to determine a strategic direction that promotes accelerated growth,” said Raj Gupta, former chairman and CEO of Rohm and Haas and a senior advisor at New Mountain, who will serve as the company’s chairman of the board. “With New Mountain as its partner, Mallinckrodt Baker will be positioned as a leading player in the speciality chemicals and materials industry.”
This story originally appeared in The Column. Click here to view that issue.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
